Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Allergan discloses novel prostanoid EP2 receptor agonists

March 17, 2010

No Comments

Inspire Pharmaceuticals reports phase II data on Azasite for blepharitis

March 16, 2010

No Comments

Ista receives action date for FDA review of XiDay sNDA

March 10, 2010

No Comments

NicOx discloses novel nitric oxide-releasing steroids

March 9, 2010

No Comments

Advanced Cell Technology's RPE cells granted FDA orphan drug status / News in Context

March 4, 2010

No Comments

NicOx grants Bausch & Lomb worldwide rights to NCX-116

March 4, 2010

No Comments

Orphan drug designation for Lithera's LIPO-102

March 3, 2010

No Comments

EMA accepts voclosporin for regulatory review

March 3, 2010

No Comments

Quark Pharmaceuticals begins dosing in phase I trial of QPI-1007 for NAION

March 2, 2010

No Comments

FDA approves Paloma Pharmaceutical's IND for phase I trial in AMD

Feb. 9, 2010

No Comments

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Ocular
RSS

Allergan discloses novel prostanoid EP2 receptor agonists

Inspire Pharmaceuticals reports phase II data on Azasite for blepharitis

Ista receives action date for FDA review of XiDay sNDA

NicOx discloses novel nitric oxide-releasing steroids

Advanced Cell Technology's RPE cells granted FDA orphan drug status / News in Context

NicOx grants Bausch & Lomb worldwide rights to NCX-116

Orphan drug designation for Lithera's LIPO-102

EMA accepts voclosporin for regulatory review

Quark Pharmaceuticals begins dosing in phase I trial of QPI-1007 for NAION

FDA approves Paloma Pharmaceutical's IND for phase I trial in AMD

Today's news in brief

Today's news in brief

Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal

Proteomics study explores how protein changes influence disease

Abbvie and Simcere enter a $1B T-cell engager deal

Ocular RSS

Ocular
RSS